Publication:
Interventions and Strategies to Improve Oral Anticoagulant Use in Patients with Atrial Fibrillation: A Systematic Review of Systematic Reviews

dc.contributor.authorSiok Shen Ngen_US
dc.contributor.authorNai Ming Laien_US
dc.contributor.authorSurakit Nathisuwanen_US
dc.contributor.authorNathorn Chaiyakunapruken_US
dc.contributor.otherTaylor's University Malaysiaen_US
dc.contributor.otherUniversity of Wisconsin-Madisonen_US
dc.contributor.otherNaresuan Universityen_US
dc.contributor.otherMonash University Malaysiaen_US
dc.contributor.otherMahidol Universityen_US
dc.contributor.otherHospital Melakaen_US
dc.date.accessioned2019-08-28T06:03:05Z
dc.date.available2019-08-28T06:03:05Z
dc.date.issued2018-07-01en_US
dc.description.abstract© 2018, Springer International Publishing AG, part of Springer Nature. Introduction: Anticoagulation therapy is the fundamental approach for stroke prevention in atrial fibrillation (AF) patients. Numerous systematic reviews comparing anticoagulation strategies have been published. We aim to summarize the efficacy and safety evidence of these strategies in AF patients from previously published systematic reviews. Methods: We searched PubMed, EMBASE and Cochrane library from inception to Feb 24th, 2017, to identify systematic reviews and meta-analyses of randomized controlled trials that assessed interventions or strategies to improve oral anticoagulant use in AF patients. Results: Thirty-four systematic reviews were eligible for inclusion but only 11 were included in the qualitative analyses, corresponding to 40 unique meta-analyses, as the remaining systematic reviews had overlapping primary studies. There was insufficient evidence to support the efficacy of genotype-guided dosing and pharmacist-managed anticoagulation clinics for stroke prevention in AF patients. Conversely, patient’s self-management and novel oral anticoagulants (NOACs), in general were superior to warfarin for preventing stroke and reducing mortality. All interventions showed comparable risk of major bleeding with warfarin. Conclusion: Findings from this overview support the superiority of NOACs and patient’s self-management for preventing stroke in AF patients. However, uncertainties remain on the benefits of genotype-guided dosing and pharmacist-managed anticoagulation clinics due to poor quality evidence, and future research is warranted.en_US
dc.identifier.citationClinical Drug Investigation. Vol.38, No.7 (2018), 579-591en_US
dc.identifier.doi10.1007/s40261-018-0641-5en_US
dc.identifier.issn11791918en_US
dc.identifier.issn11732563en_US
dc.identifier.other2-s2.0-85044257797en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/123456789/46571
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85044257797&origin=inwarden_US
dc.subjectMedicineen_US
dc.titleInterventions and Strategies to Improve Oral Anticoagulant Use in Patients with Atrial Fibrillation: A Systematic Review of Systematic Reviewsen_US
dc.typeReviewen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85044257797&origin=inwarden_US

Files

Collections